Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel, Prasugrel, and Ticagrelor), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or, Prasugrel, or Ticagrelor When Administered After a Single Subcutaneous Dose of the P2Y12 Antagonist ACT-246475 in Healthy Male and Female Subjects

Trial Profile

Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel, Prasugrel, and Ticagrelor), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or, Prasugrel, or Ticagrelor When Administered After a Single Subcutaneous Dose of the P2Y12 Antagonist ACT-246475 in Healthy Male and Female Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs ACT 246475 (Primary) ; Clopidogrel; Prasugrel; Ticagrelor
  • Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery disease
  • Focus Pharmacodynamics
  • Sponsors Idorsia Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2018 Results (n=8) published in the Journal of Clinical Pharmacology.
    • 07 Jun 2018 Planned number of patients changed from 72 to 108.
    • 07 Jun 2018 Planned End Date changed from 31 Jan 2019 to 30 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top